Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for ¹⁷⁷Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer
April 24, 2023 07:30 ET
|
Lantheus Holdings, Inc.; POINT Biopharma Global Inc.
BEDFORD, Mass. and INDIANAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics,...
Lantheus to Host First Quarter 2023 Earnings Conference Call and Webcast on May 4, 2023, at 8:00 a.m. Eastern Time
April 20, 2023 08:00 ET
|
Lantheus Holdings, Inc.
BEDFORD, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday,...
Lantheus Announces Two Key Executive Promotions
March 17, 2023 08:35 ET
|
Lantheus Holdings, Inc.
BEDFORD, Mass., March 17, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and...
Lantheus Reports Fourth Quarter and Full Year 2022 Financial Results
February 23, 2023 07:00 ET
|
Lantheus Holdings, Inc.
Worldwide revenue of $263.2 million and $935.1 million for the fourth quarter and full year 2022, representing increases of 103.1% and 119.9% over the prior year periods, respectivelyGAAP net loss of...
Lantheus Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels
February 16, 2023 08:30 ET
|
Lantheus Holdings, Inc.
BEDFORD, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and...
Lantheus to Host Fourth Quarter and Full Year 2022 Earnings Conference Call and Webcast on February 23, 2023, at 8:00 a.m. Eastern Time
February 09, 2023 08:00 ET
|
Lantheus Holdings, Inc.
BEDFORD, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday,...
Lantheus to Present Piflufolastat F 18 Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
February 08, 2023 08:30 ET
|
Lantheus Holdings, Inc.
BEDFORD, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and...
Lantheus Announces Acquisition of Cerveau Technologies, Inc., Expanding Imaging Pipeline into Alzheimer’s Disease
February 06, 2023 16:03 ET
|
Lantheus Holdings, Inc.
BEDFORD, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and...
Lantheus to Present at the J.P. Morgan 2023 Healthcare Conference
January 04, 2023 08:30 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics,...
Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with POINT Biopharma
December 20, 2022 08:30 ET
|
Lantheus Holdings, Inc.
NORTH BILLERICA, Mass., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics,...